A bull market will eventually follow the challenging and volatile times we face, and, based on history, this bull run is ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Paul Vieira covers Canada for The Wall Street Journal, and is based in Ottawa.

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

The United States is already falling behind China in countless technological advancements, thanks to several Biden-era policies.

Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

How valuable would it be to a company who manufactures vaccines if they had a product that the government mandated to be used on every animal? Even the chickens in your back yard? What if the bird flu ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...